Chinese Social Media Giant Xiaohongshu Eyes Hong Kong IPO at Over $70 Billion Valuation 
US-Iran De-Escalation Shifts Washington’s Focus to AI Regulation and Crypto Legislation 
Hyundai to Acquire SoftBank’s Remaining Boston Dynamics Stake for $325 Million 
Kingboard Holdings Shares Surge After HK$11.77 Billion Block Trade to Expand PCB and AI Supply Chain Business 
Trump Says Anthropic No Longer Seen as National Security Threat 
SpaceX Stock Slides After IPO Rally as Valuation Concerns Grow 
Ukrainian Drone Makers Target Japan and Asia Defense Market 
SK Hynix Overtakes Samsung as South Korea’s Most Valuable Company 
Samsung Gains Interest from BYD, Google, AMD as AI Chip Demand Strains TSMC Capacity 
Google’s Open-Source AI Data Center Cooling Design Raises Commoditization Concerns 
Jio IPO Filing Nears as Reliance Targets $4 Billion Market Debut 
JPMorgan Sees Strong Strategic Value in Potential AbbVie Acquisition of Apogee Therapeutics 
Google Gemini Co-Lead Noam Shazeer Leaves for OpenAI Amid AI Talent Race 
Saudi Aramco Explores Sulphur Business Stake Sale to Raise Billions 
Qantas Unveils Wellness-Focused Nonstop Sydney-London Flights to Reduce Jet Lag 
Emasan AG, the investment arm of the Sandoz family, has sold a significant stake in Swiss pharmaceutical giant Novartis (SIX:NOVN), generating 2.6 billion Swiss francs ($2.90 billion).
The sale, conducted through an accelerated bookbuilding process, saw Emasan AG offload 26.5 million Novartis shares at 98.25 Swiss francs each. Goldman Sachs, acting as the bookrunner, confirmed the transaction on Wednesday.
This move marks a substantial capital realization for Emasan AG, highlighting a strategic shift in the investment portfolio of the Sandoz family. Novartis, a global leader in pharmaceuticals, has been a key holding for Emasan AG, making this divestment particularly notable for investors tracking the Swiss stock market.
The deal is expected to impact Novartis’s share performance, given the scale of the transaction. Market analysts are closely watching how this sell-off influences investor sentiment and Novartis’s future stock valuation.
This article was generated with AI assistance and reviewed by an editor.
